CIK 0000318154
- Large accelerated filer
AMGEN INC
Sign in to watch- Ticker
- AMGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 953540776
- Phone
- +1 805-447-1000
- Business address
- ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-10 | SUGAR RONALD D Director | Exercise or conversion · Nqso (Right to Buy) | −1,000 | 2,000 | ||
| 2021-03-02 | Santos Esteban EVP, Operations | Grant or award | +8,725 | 53,251 | ||
| 2021-03-02 | REESE DAVID M EVP, Research and Development | Grant or award | +2,803 | 43,715 | ||
| 2021-03-02 | Piacquad David SVP, Business Development | Grant or award | +2,648 | 45,504 | ||
| 2021-03-02 | Louie Linda H. VP, Finance & CAO | Grant or award | +467 | 8,113 | ||
| 2021-03-02 | Johnston Lori A EVP, HR | Grant or award | +5,608 | 37,682 | ||
| 2021-03-02 | Grygiel Nancy A. SVP & CCO | Grant or award | +1,245 | 12,401 | ||
| 2021-03-02 | Graham Jonathan P EVP, Gen. Counsel & Secy. | Grant or award | +8,725 | 48,670 | ||
| 2021-03-02 | Gordon Murdo EVP Global Commercial Ops | Grant or award | +17,989 | 50,159 | ||
| 2021-03-02 | Bradway Robert A Chairman, CEO and President | Grant or award | +38,953 | 609,806 | ||
| 2021-02-18 | Bradway Robert A Chairman, CEO and President | Exercise or conversion | +73,500 | $54.69 | $4.0M | 618,380 |
| 2021-02-18 | Bradway Robert A Chairman, CEO and President | Shares withheld for taxes | −47,527 | $235.61 | $11.2M | 570,853 |
| 2021-02-18 | Bradway Robert A Chairman, CEO and President | Exercise or conversion · Nqso (Right to Buy) | −73,500 | 0 | ||
| 2021-02-16 | REESE DAVID M EVP, Research and Development | Exercise or conversion | +2,300 | $54.69 | $126K | 42,059 |
| 2021-02-16 | REESE DAVID M EVP, Research and Development | Shares withheld for taxes | −1,147 | $237.21 | $272K | 40,912 |
| 2021-02-16 | REESE DAVID M EVP, Research and Development | Exercise or conversion · Nqso (Right to Buy) | −2,300 | 0 | ||
| 2021-02-10 | SUGAR RONALD D Director | Exercise or conversion | +1,000 | $71.64 | $72K | 16,805 |
| 2021-02-10 | SUGAR RONALD D Director | Sale | −1,000 | $238.40 | $238K | 15,805 |
| 2021-02-10 | SUGAR RONALD D Director | Exercise or conversion · Nqso (Right to Buy) | −1,000 | 3,000 | ||
| 2021-02-08 | Williams R Sanders Director | Sale | −250 | $237.99 | $59K | 4,659 |
Page 34 of 35 · 698 trades